MVA-hHBV

GSKVX000000008885 (MVA-hHBV) is a therapeutic viral vector vaccine candidate developed by GSK for the treatment of chronic hepatitis B. It utilizes a Modified Vaccinia Ankara (MVA) vector engineered to express a fusion protein containing three key hepatitis B virus (HBV) antigens: the surface antigen (HBsAg), the core antigen (HBcAg), and a truncated, enzymatically inactive polymerase. The vaccine is designed to stimulate a robust, broad, and functional T-cell response (both CD4+ and CD8+) to help clear HBV-infected hepatocytes and overcome the immune exhaustion characteristic of chronic infection. In clinical development, MVA-hHBV is typically administered as part of a heterologous prime-boost regimen, often serving as the boost following a priming dose with a chimpanzee adenovirus vector (ChAd155-hHBV). This regimen is frequently evaluated in combination with an adjuvanted recombinant protein vaccine (GSK3528869A) to maximize both humoral and cellular immune responses, with the ultimate goal of achieving a functional cure (sustained HBsAg loss).

Other names

Modified Vaccinia Ankara-based Hepatitis B VaccineGSK HBV MVA viral vector vaccine